These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 22797450

  • 1. Lipid-related markers and cardiovascular disease prediction.
    Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D, Saleheen D, Ballantyne CM, Psaty BM, Sundström J, Ridker PM, Nagel D, Gillum RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RP, Assmann G, D'Agostino RB, Dagenais GR, Cooper JA, Kromhout D, Onat A, Tipping RW, Gómez-de-la-Cámara A, Rosengren A, Sutherland SE, Gallacher J, Fowkes FG, Casiglia E, Hofman A, Salomaa V, Barrett-Connor E, Clarke R, Brunner E, Jukema JW, Simons LA, Sandhu M, Wareham NJ, Khaw KT, Kauhanen J, Salonen JT, Howard WJ, Nordestgaard BG, Wood AM, Thompson SG, Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J.
    JAMA; 2012 Jun 20; 307(23):2499-506. PubMed ID: 22797450
    [Abstract] [Full Text] [Related]

  • 2. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease.
    Welsh C, Celis-Morales CA, Brown R, Mackay DF, Lewsey J, Mark PB, Gray SR, Ferguson LD, Anderson JJ, Lyall DM, Cleland JG, Jhund PS, Gill JMR, Pell JP, Sattar N, Welsh P.
    Circulation; 2019 Aug 13; 140(7):542-552. PubMed ID: 31216866
    [Abstract] [Full Text] [Related]

  • 3. Glycated hemoglobin measurement and prediction of cardiovascular disease.
    Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, Kaptoge S, Kondapally Seshasai SR, Thompson A, Sarwar N, Willeit P, Ridker PM, Barr EL, Khaw KT, Psaty BM, Brenner H, Balkau B, Dekker JM, Lawlor DA, Daimon M, Willeit J, Njølstad I, Nissinen A, Brunner EJ, Kuller LH, Price JF, Sundström J, Knuiman MW, Feskens EJ, Verschuren WM, Wald N, Bakker SJ, Whincup PH, Ford I, Goldbourt U, Gómez-de-la-Cámara A, Gallacher J, Simons LA, Rosengren A, Sutherland SE, Björkelund C, Blazer DG, Wassertheil-Smoller S, Onat A, Marín Ibañez A, Casiglia E, Jukema JW, Simpson LM, Giampaoli S, Nordestgaard BG, Selmer R, Wennberg P, Kauhanen J, Salonen JT, Dankner R, Barrett-Connor E, Kavousi M, Gudnason V, Evans D, Wallace RB, Cushman M, D'Agostino RB, Umans JG, Kiyohara Y, Nakagawa H, Sato S, Gillum RF, Folsom AR, van der Schouw YT, Moons KG, Griffin SJ, Sattar N, Wareham NJ, Selvin E, Thompson SG, Danesh J.
    JAMA; 2014 Mar 26; 311(12):1225-33. PubMed ID: 24668104
    [Abstract] [Full Text] [Related]

  • 4. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.
    Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE.
    JAMA; 2005 Jul 20; 294(3):326-33. PubMed ID: 16030277
    [Abstract] [Full Text] [Related]

  • 5. Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study.
    Mora S, Buring JE, Ridker PM, Cui Y.
    Ann Intern Med; 2011 Dec 06; 155(11):742-50. PubMed ID: 22147713
    [Abstract] [Full Text] [Related]

  • 6. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
    Khera AV, Demler OV, Adelman SJ, Collins HL, Glynn RJ, Ridker PM, Rader DJ, Mora S.
    Circulation; 2017 Jun 20; 135(25):2494-2504. PubMed ID: 28450350
    [Abstract] [Full Text] [Related]

  • 7. Apolipoprotein Particle and Cardiovascular Risk Prediction (from a Prospective Cohort Study).
    Su X, Wang M, Zuo Y, Wen J, Zhai Q, Zhang Y, Xia Z, Li Y, He Y.
    Am J Cardiol; 2023 Aug 15; 201():34-41. PubMed ID: 37352662
    [Abstract] [Full Text] [Related]

  • 8. Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses.
    Sun L, Pennells L, Kaptoge S, Nelson CP, Ritchie SC, Abraham G, Arnold M, Bell S, Bolton T, Burgess S, Dudbridge F, Guo Q, Sofianopoulou E, Stevens D, Thompson JR, Butterworth AS, Wood A, Danesh J, Samani NJ, Inouye M, Di Angelantonio E.
    PLoS Med; 2021 Jan 15; 18(1):e1003498. PubMed ID: 33444330
    [Abstract] [Full Text] [Related]

  • 9. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Mora S, Glynn RJ, Boekholdt SM, Nordestgaard BG, Kastelein JJ, Ridker PM.
    J Am Coll Cardiol; 2012 Apr 24; 59(17):1521-8. PubMed ID: 22516441
    [Abstract] [Full Text] [Related]

  • 10. Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPIC-Heidelberg cohort.
    Katzke VA, Sookthai D, Johnson T, Kühn T, Kaaks R.
    BMC Med; 2017 Dec 19; 15(1):218. PubMed ID: 29254484
    [Abstract] [Full Text] [Related]

  • 11. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals.
    Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O'Leary D, Carr JJ, Goff DC, Greenland P, Herrington DM.
    JAMA; 2012 Aug 22; 308(8):788-95. PubMed ID: 22910756
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular risk prediction: Can Systematic Coronary Risk Evaluation (SCORE) be improved by adding simple risk markers? Results from the Copenhagen City Heart Study.
    Graversen P, Abildstrøm SZ, Jespersen L, Borglykke A, Prescott E.
    Eur J Prev Cardiol; 2016 Sep 22; 23(14):1546-56. PubMed ID: 26976846
    [Abstract] [Full Text] [Related]

  • 13. Non-High-Density Lipoprotein Cholesterol Levels From Childhood to Adulthood and Cardiovascular Disease Events.
    Wu F, Jacobs DR, Daniels SR, Kähönen M, Woo JG, Sinaiko AR, Viikari JSA, Bazzano LA, Steinberger J, Urbina EM, Venn AJ, Raitakari OT, Dwyer T, Juonala M, Magnussen CG.
    JAMA; 2024 Jun 04; 331(21):1834-1844. PubMed ID: 38607340
    [Abstract] [Full Text] [Related]

  • 14. Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis.
    Knowlton N, Wages JA, Centola MB, Giles J, Bathon J, Quiroga C, Alaupovic P.
    Arthritis Care Res (Hoboken); 2012 Jul 04; 64(7):993-1000. PubMed ID: 22337612
    [Abstract] [Full Text] [Related]

  • 15. Sex-Related Differences of the Effect of Lipoproteins and Apolipoproteins on 10-Year Cardiovascular Disease Risk; Insights from the ATTICA Study (2002-2012).
    Kouvari M, Panagiotakos DB, Chrysohoou C, Georgousopoulou EN, Tousoulis D, Pitsavos AC.
    Molecules; 2020 Mar 26; 25(7):. PubMed ID: 32225033
    [Abstract] [Full Text] [Related]

  • 16. Comprehensive Assessment of Lipid Markers in Cardiovascular Events Prediction.
    Inoue N, Morikawa S, Murohara T.
    Int Heart J; 2024 Sep 30; 65(5):792-799. PubMed ID: 39261028
    [Abstract] [Full Text] [Related]

  • 17. Hierarchical modelling of blood lipids' profile and 10-year (2002-2012) all cause mortality and incidence of cardiovascular disease: the ATTICA study.
    Nomikos T, Panagiotakos D, Georgousopoulou E, Metaxa V, Chrysohoou C, Skoumas I, Antonopoulou S, Tousoulis D, Stefanadis C, Pitsavos C, ATTICA Study group.
    Lipids Health Dis; 2015 Sep 15; 14():108. PubMed ID: 26370413
    [Abstract] [Full Text] [Related]

  • 18. C-reactive protein, fibrinogen, and cardiovascular disease prediction.
    Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Björkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D'Agostino RB, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engström G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jørgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J.
    N Engl J Med; 2012 Oct 04; 367(14):1310-20. PubMed ID: 23034020
    [Abstract] [Full Text] [Related]

  • 19. Sex and time differences in the associations of non-high-density lipoprotein cholesterol versus other lipid and lipoprotein factors in the prediction of cardiovascular death (The Rancho Bernardo Study).
    von Mühlen D, Langer RD, Barrett-Connor E.
    Am J Cardiol; 2003 Jun 01; 91(11):1311-5. PubMed ID: 12767422
    [Abstract] [Full Text] [Related]

  • 20. Use of lipoprotein particle measures for assessing coronary heart disease risk post-American Heart Association/American College of Cardiology guidelines: the Multi-Ethnic Study of Atherosclerosis.
    Steffen BT, Guan W, Remaley AT, Paramsothy P, Heckbert SR, McClelland RL, Greenland P, Michos ED, Tsai MY.
    Arterioscler Thromb Vasc Biol; 2015 Feb 01; 35(2):448-54. PubMed ID: 25477346
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.